Market research including initial interviews with US health care practitioners as well as US payers demonstrated a strong willingness to consider prescribing the investigational precision medicine Diamyd® for Type 1 Diabetes and pricing in the range of USD 200,000. Diamyd® is currently being evaluated in the registrational Phase 3 trial DIAGNODE-3 in patients recently diagnosed with Type 1 Diabetes that carry the HLA DR3-DQ2 haplotype.
Pricing Insights: The research, undertaken by the US-based consultancy, Kondrad Consulting Group, involved detailed interviews with both national and regional payers, collectively responsible for healthcare coverage of approximately 77 million commercial lives in the United States. These interviews suggest a potential price range of USD 194,000 - 240,000 for Diamyd®, based on effective delivery of its unique product profile targeted at a specific genetic subgroup of type 1 diabetes patients.
Healthcare Practitioner Feedback: Conversations with a select group of primary care, endocrinologist and interventional radiologist physicians shed light on various aspects of the patient journey and treatment preferences. The willingness to consider prescribing Diamyd® was very strong. Interventional radiologists, in particular, found the ultrasound guided injection procedure to be straightforward and virtually painless, aligning with previous observations made by Diamyd Medical.
Educational Needs and Market Preparation: The research highlighted some gaps in awareness regarding type 1 diabetes staging and the diversity in first-line therapy approaches. These findings underscore the importance of continuous educational efforts in tandem with the introduction of new treatments like Diamyd®. The research pointed to Integrated Delivery Networks (IDNs) as a natural and effective delivery channel for Diamyd® outpatient treatment. IDNs are networks of hospitals, physicians, and clinics covering a broad continuum of outpatient care from diagnostics to procedures to surgeries.
